TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27509600
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acupuncture method of 'Xingnao Kaiqiao' and oral administration of nifedipine)
Study: 23082123
Drug: Oseltamivir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir treatment (75 mg twice a day for 5 days)
Study: 23082123
Drug: Oseltamivir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir treatment and prophylaxis (75 mg once a day for 10 days)
Study: 9449256
Drug: Cefpirome (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (2 g twice daily)
Study: 9449256
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g three times daily)
Study: 25644856
Drug: Salsalate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (4 g day(-1) for 4 weeks)
Study: 19094160
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg t.i.d.) for 5 days with transdermal rotigotine patch (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Study: 19094160
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine treatment (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Study: 17557948
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of breast cancer-specific print materials and step pedometers
Study: 16284984
Drug: Maintenance/consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance/consolidation chemotherapy
Study: 12474702
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 300 mg
Study: 12474702
Drug: Pizotifen 1.5
Normalized name: Pizotifen 1.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 1.5 mg
Study: 28562117
Drug: Omega-3 (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (425 mg/capsule, 2 capsules/day)
Study: 28562117
Drug: Soybean isoflavones
Normalized name: Soybean isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean isoflavones (54.4 mg/tablet, 2 tablets/day)
Study: 21806580
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation (8 L/min via face mask for 2 h)
Study: 21885723
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation
Study: 19336539
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 3 mg kg(‐1) h(‐1)
Study: 19336539
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 6 mg kg(‐1) h(‐1)
Study: 16927064
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.2 g/kg per day)
Study: 428228
Drug: Prostaglandin vaginal
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin vaginal suppositories
Study: 31070741
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment control
Study: 23605506
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 100 μg
Study: 23605506
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 200 μg
Study: 23605506
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 400 μg
Study: 23605506
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 600 μg
Study: 23605506
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 800 μg
Study: 11704752
Drug: One-week application
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week application of terbinafine cream
Study: 11704752
Drug: Four-week application
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-week application of terbinafine cream
Study: 31322804
Drug: Physiogel® moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiogel® moisturizing creams (three test products)
Study: 30236246
Drug: FNB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNB with LIA of the posterior capsule
Study: 23897949
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation therapy
Study: 22348643
Drug: Manual Chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual Chest Therapy (MCT)
Study: 16012284
Drug: Olanzapine (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5‐20 mg/d)
Study: 16012284
Drug: Haloperidol (3‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3‐15 mg/d)
Study: 16012284
Drug: Olanzapine (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10‐20 mg/d)
Study: 16012284
Drug: Risperidone (4‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4‐12 mg/d)
Study: 11789190
Drug: HANS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HANS treatment (4 treatments of 30 min each for the first 3 days, twice a day for 3 more days, and once a day for 7 days; total 15 days)
Study: 8861236
Drug: 27.3 mg
Normalized name: sodium fluoride 27.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27.3 mg saccharin
Study: 1623692
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg every 8 hours for 6 days)
Study: 6704647
Drug: Iohexol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (40 ml, 350 mg I/ml)
Study: 29126319
Drug: Cholecalciferol 300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 300,000 IU initially, then 1400 IU cholecalciferol and 500 mg of calcium daily for 150 days
Study: 15842551
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin IV as a 1 h infusion
Study: 15842551
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g before infusion, 5 g after infusion, 10 g at 2, 4, and 8 h)
Study: 15842551
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4, and 8 h after drug administration)
Study: 12372724
Drug: Hormonal therapies
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapies
Study: 8129189
Drug: Picotamide, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide, 300 mg three times a day
Study: 8129189
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three identical tablets each day)
Study: 2782273
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30, 60, or 90 mg once daily)
Study: 2782273
Drug: Sustained-release propranolol
Normalized name: propranolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release propranolol (80, 160, or 240 mg once daily)
Study: 31189517
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (14 mg once daily for 26 weeks)
Study: 18298423
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.005% ointment (FP) twice daily during the acute phase and twice weekly during the maintenance phase
Study: 18298423
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment twice weekly on consecutive days
Study: 17889314
Drug: Bupropion +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion + nicotine patch
Study: 15464333
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tadalafil
Study: 15464333
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tadalafil
Study: 9725545
Drug: [14C] irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: [14C] irbesartan orally as a solution (50 mg)
Study: 9725545
Drug: [14C] irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: [14C] irbesartan orally as a solution (150 mg)
Study: 9725545
Drug: Irbesartan capsule
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan capsule (50 mg)
Study: 9725545
Drug: [14C] irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: [14C] irbesartan as a 30‐minute intravenous infusion (50 mg)
Study: 8296814
Drug: Oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naproxen (500 mg)
Study: 2690225
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment with 2x (COPP + ABVD) followed by 20 or 40 Gy EF radiation (HD1 protocol)
Study: 2690225
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with 3x (COPP + ABVD) followed by consolidation therapy (20 Gy IF or further chemotherapy) or salvage therapy (40Gy or 4x CEVD chemotherapy) (HD3 protocol)
Study: 999494
Drug: Propranolol (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20-40 mg every 4 hours, increased to 280-2320 mg per day)
Study: 999494
Drug: Dexpropranolol (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpropranolol (900 mg daily for 5 days)
Study: 12384358
Drug: Pneumococcal isolates
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal isolates resistant to penicillin (MIC, > or =2.0 micro g/ml)
Study: 10063913
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (30 ml)
Study: 10063913
Drug: Ethyl alcohol
Normalized name: Ethyl alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl alcohol (60 ml, 40% v/v)
Study: 10063913
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (30 ml) pretreatment with ethyl alcohol
Study: 28371689
Drug: Take-home self-administered
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home self-administered sublingual buprenorphine-naloxone weekly (mean dose, 22.7±5.7mg)
Study: 28371689
Drug: Take-home self-administered
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home self-administered sublingual buprenorphine-naloxone weekly
Study: 26437830
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g freeze-dried wild blueberry (WBB) powder
Study: 26437830
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g freeze-dried wild blueberry (WBB) powder
Study: 17923591
Drug: Combination ARB
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ARB plus ACE inhibitor
Study: 8527688
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice daily) + Ambroxol (30 mg thrice daily)
Study: 2109531
Drug: rIFN‐gamma at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma at 0.01 mg/m2
Study: 2109531
Drug: rIFN‐gamma at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma at 0.1 mg/m2
Study: 2109531
Drug: rIFN‐gamma at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma at three dose levels (0.01 mg/m2, 0.05 mg/m2, 0.1 mg/m2)
Study: 2109531
Drug: rIFN‐gamma at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma at 0.05 mg/m2 for 6 weeks
Study: 30312135
Drug: Fucoidan 500
Normalized name: Fucidin
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucoidan 500 mg twice daily for 90 days
Study: 30312135
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily for 90 days
Study: 25899425
Drug: Memantine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine therapy
Study: 21857901
Drug: DNA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA (4 mg i.m. by Biojector) at 0, 1 and 2 months, followed by rAd5 (10(10) PU i.m. by needle/syringe) at 6 months
Study: 20664352
Drug: Oesomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oesomeprazole 40 mg once daily for 7 days
Study: 7503088
Drug: Radioiodine, surgery,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine, surgery, or ethanol injection for hot nodules
Study: 2152339
Drug: Methotrexate administered
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate administered intravenously (group 2, 17 patients)
Study: 15483371
Drug: Alcohol (0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.65 g alcohol/kg body weight)
Study: 29249774
Drug: Lifestyle support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle support program administered by pharmacists (brochures and healthy lifestyle advice using motivational interviewing methods) over a 12-week period
Study: 12375333
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tramadol tablets
Study: 12375333
Drug: Normal release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal release tramadol capsules (50 mg) taken 3 or 4 times daily
Study: 9951568
Drug: Psychotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (weekly interpersonal psychotherapy)
Study: 2189979
Drug: Daily suction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily suction and débridement with intravenous mezlocillin
Study: 2189979
Drug: Daily suction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily suction and débridement with intravenous ceftazidime
Study: 2189979
Drug: Daily suction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily suction and débridement without antibiotics (control)
Study: 2189979
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients treated initially with antibiotics
Study: 25707
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (250 mg to 500 mg)
Study: 25707
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg to 100 mg)
Study: 26677829
Drug: Eccentric overload
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric overload training (ECC) group performed 6 weeks of eccentric overload training (twice weekly, 4 sets of 7 repetitions in a Yoyo squat device) before the running intervention.
Study: 24599421
Drug: Selective estrogen-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen-receptor modulators
Study: 7528129
Drug: β-blockers (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (general use)
Study: 7528129
Drug: β-blockers (late
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (late use)
Study: 7528129
Drug: β-blockers (heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (heart failure)
Study: 2973571
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fenoterol hydrobromide
Study: 30100558
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT) with cilostazol
Study: 27787471
Drug: Plyometric training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plyometric training (20 min·d, twice a week, during 12 weeks)
Study: 15244255
Drug: CNOP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNOP chemotherapy
Study: 7935030
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens with cyclic medrogestone, 5 mg daily during the last 12 days of each 28 days treatment cycle
Study: 28406752
Drug: PCECV-G (German
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCECV-G (German batch)
Study: 28406752
Drug: PCECV-I and
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCECV-I and PCECV-G (all groups)
Study: 16724575
Drug: Fixed bacterium
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed bacterium combination of Lactobacillus gasseri and Bifidobacterium longum
Study: 7483113
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 66 mg ferrous iron (as fumarate) daily
Study: 10922094
Drug: Enema preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema preparation
Study: 7083601
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 160 mg daily by mouth
Study: 29565951
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.25% bupivacaine plus 1 µg/kg dexmedetomidine (GD group)
Study: 29565951
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.25% bupivacaine only (GB group)
Study: 27436880
Drug: Pravastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin treatment arm
Study: 24798770
Drug: dolutegravir/abacavir/lamivudine FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: dolutegravir/abacavir/lamivudine FDC tablet
Study: 24798770
Drug: dolutegravir/abacavir/lamivudine FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: dolutegravir/abacavir/lamivudine FDC tablet with a high-fat meal
Study: 11887531
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) for Class I cavity preparations
Study: 11887531
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) for Class II cavity preparations
Study: 11887531
Drug: Conventional cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cavity preparation for Class II cavity preparations
Study: 11887531
Drug: Conventional cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cavity preparation for Class I cavity preparations
Study: 11887531
Drug: Amalgam restorations
Normalized name: DENTAL AMALGAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amalgam restorations in Class I conventional preparations
Study: 9790334
Drug: rhGH (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.2 mg/kg/day subcutaneously)
Study: 7631514
Drug: High-dose Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Edmonston-Zagreb strain (10(5.6) TDIC50)
Study: 7631514
Drug: Low-dose Connaught
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Connaught strain (10(3) TCID50)
Study: 7631514
Drug: Medium-dose Schwarz
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose Schwarz strain (10(4) TCID50)
Study: 319717
Drug: Aerosolized delta9-tetrahydrocannabinol
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized delta9-tetrahydrocannabinol (5 to 20 mg)
Study: 319717
Drug: Aerosolized delta9-tetrahydrocannabinol
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized delta9-tetrahydrocannabinol (5 mg)
Study: 19164402
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise held twice weekly for five weeks
Study: 16467067
Drug: Nebulised bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised bronchodilator (ipratropium 0.5 mg + salbutamol 2.5 mg) with 50% O2
Study: 16467067
Drug: Nebulised bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised bronchodilator (ipratropium 0.5 mg + salbutamol 2.5 mg) alone
Study: 12468808
Drug: Amitriptyline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (titrated from 10 to 75 mg in extended-release form)
Study: 7698617
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg t.i.d. for 2 weeks (group O)
Study: 7698617
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg t.i.d. + Amoxicillin 500 mg q.i.d. for 2 weeks (group O + A)
Study: 23134
Drug: Oral theophylline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline, placebo aerosol (TP)
Study: 23134
Drug: Oral placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo, rimiterol aerosol (PR)
Study: 23134
Drug: Oral theophylline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline, rimiterol aerosol (TR)
Study: 23134
Drug: Oral placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo, placebo aerosol (PP)
Study: 30186989
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ceftizoxime powder and clotrimazole ointment
Study: 19681572
Drug: 6-week restorative
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week restorative care educational program (30 minutes weekly)